Core Insights - Gan Li Pharmaceutical announced the appointment of Jia Ting as Corporate Vice President and Chief Medical Officer, responsible for the company's operations in Europe and the United States [1] - The Chairman and CEO of Gan Li Pharmaceutical, Chen Wei, expressed confidence that Jia Ting's involvement will accelerate the global registration and clinical development of new drugs [1] Company Overview - Jia Ting holds a medical doctorate from Karolinska Institute in Sweden and has over 15 years of experience in research and global clinical development in metabolic diseases, focusing on diabetes, obesity, kidney diseases, and other chronic metabolic conditions [1] - Prior to joining Gan Li Pharmaceutical, Jia Ting worked at Novo Nordisk, overseeing the lifecycle management of multiple innovative drugs and successfully facilitating product approvals and indication expansions in major markets including the US, Europe, and China [1]

Core Viewpoint - Fosun Pharma (600196)(02196) announced a licensing agreement with Sitala for the development, production, and commercialization of FXS6837 and related products in a global scope excluding China (including Hong Kong, Macau, and Taiwan) [1] Group 1 - The licensing agreement allows Fosun Pharma's subsidiary to obtain rights for human and animal disease diagnostics and treatments [1] - Fosun Pharma's subsidiary can acquire shares of Sitala valued at $5 million at zero cost based on this licensing arrangement [1] - This collaboration is expected to accelerate the clinical development and commercialization of licensed products globally and expand the group's innovative product portfolio overseas [1]

智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司复星医药产业授予 Sitala 于许可区域 (即除中国<包括港澳台地区>外的全球范围)及领域(即人类、动物疾病的诊断和治疗)开发、生产及商业 化 FXS6837 及含有该活性成分的产品的权利。同时，基于本次许可的安排，复星医药产业(或其指定关 联方)可以零对价获得价值 500 万美元的 Sitala 的股份。 公告称，本次合作有利于进一步加快许可产品在全球范围的临床开发和商业化进程，并持续拓展集团创 新产品的海外布局。 ...